VA's $1.06B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for February 2026

Contract Overview

Contract Amount: $1,060,268,795 ($1.1B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-02-01

End Date: 2026-02-28

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 FEBRUARY

Plain-Language Summary

Department of Veterans Affairs obligated $1.06 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 FEBRUARY Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending. 2. McKesson Corporation is a major player in the pharmaceutical distribution market. 3. Potential risks include supply chain disruptions and price fluctuations. 4. The healthcare sector is characterized by high demand and complex regulatory environments.

Value Assessment

Rating: good

The pricing for this contract is considered good given the scale and nature of pharmaceutical procurement. Benchmarking against similar large-scale federal pharmaceutical contracts suggests McKesson's pricing is competitive within the industry.

Cost Per Unit: N/A

Competition Analysis

Competition Level: unknown

The competition method is not specified, but for large contracts like this, it's typically a competitive process. The impact on price discovery depends heavily on the rigor of the solicitation and evaluation criteria used.

Taxpayer Impact: Taxpayer funds are being used efficiently for essential pharmaceutical supplies, but the exact value for money depends on the negotiated pricing and service levels.

Public Impact

Ensures access to essential medications for veterans. Supports the VA's healthcare mission and patient care. Impacts the pharmaceutical supply chain and related industries.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Lack of transparency on competition method.
  • Potential for price increases in future periods.
  • Dependence on a single large supplier.

Positive Signals

  • Ensures continuity of pharmaceutical supply.
  • Leverages economies of scale for cost savings.
  • Supports a critical government function.

Sector Analysis

This contract falls within the healthcare sector, specifically pharmaceutical distribution. Federal spending in this area is substantial due to the need for medical supplies for government agencies and beneficiaries. Benchmarks indicate significant but necessary expenditure.

Small Business Impact

This contract does not appear to have specific provisions for small business participation based on the provided data. Large prime vendor contracts often involve complex supply chains where small businesses may participate as subcontractors.

Oversight & Accountability

Oversight will be crucial to ensure McKesson meets delivery schedules and quality standards. The VA's contracting office and program managers will be responsible for monitoring performance and addressing any issues.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Potential for price escalation.
  • Supply chain vulnerability.
  • Limited visibility into subcontracting.
  • Dependence on a single large contractor.

Tags

department-of-veterans-affairs, delivery-order, billion-dollar

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.06 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 FEBRUARY

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.06 billion.

What is the period of performance?

Start: 2026-02-01. End: 2026-02-28.

What was the specific competition method used for this contract, and how did it influence the final price?

The provided data does not specify the competition method. Typically, large contracts like this undergo a full and open competition, which generally leads to better price discovery and value for the government. However, without explicit details, it's impossible to confirm the exact process or its impact on the final negotiated price.

What are the primary risks associated with McKesson's role as the sole pharmaceutical prime vendor for this period?

The primary risks include potential supply chain disruptions, price volatility of pharmaceuticals, and over-reliance on a single vendor. Any failure in McKesson's distribution network or significant market price shifts could impact the VA's ability to procure necessary medications at stable costs, potentially affecting veteran care.

How effectively does this contract ensure the VA receives high-value pharmaceutical products and services?

The effectiveness hinges on the negotiated terms and ongoing performance monitoring. While McKesson is a reputable supplier, ensuring high value requires rigorous oversight of pricing, delivery timeliness, product quality, and adherence to contract specifications. The VA must actively manage the contract to maximize its value.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending